UniQure (NASDAQ: QURE ) stock is on the rise Tuesday after the company provided investors with interim clinical data from Phase I/II clinical trials for AMT-130. These clinical trials are evaluating the use of AMT-130 as a treatment for Huntington’s disease. This data comes after 24 months of follow-up data was collected from 29 study participants.
This study included both high-dose and low-dose patients. The high-dose patients saw an 80% slowing in disease progression, while the low-dose patients saw a 30% slowing. Patients in the study also saw a mean 11% reduction in CSF NfL compared to baseline.
Walid Abi-Saab, M.D., Chief Medical Officer at uniQure, said this about the data: What’s Next for QURE Stock? The company is already preparing its next steps for this study.
That includes a meeting with regulators later this year. It’s also planning for a third cohort of the study in the second half of 2025. Finally, it expects another interim analysis in mid-2025.
QURE stock is up 51% as of Tuesday morning. That comes with more than 23 million shares traded, as compared to a daily average of 574,000 shares. Below are more stock market stories worth diving into! We have all of the hottest stock market news available on Tuesday! A few examples include what’s going on with shares of Soligenix (NASDAQ: SNGX ), Lucid Motors (NASDAQ: LCID ) and Corning (NYSE: GLW ) stock today.
All of that info is ready at the following links! More Stock Market News on Tuesday Why Is Soligenix .
